Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach

References

• CE SSH, Harris NL, Jaffe ES, et al., editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon France: IARC Press; 2017.
   Google Scholar
• Smith A, Crouch S, Howell D, et al. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39(6):1103–1112.
   PubMed Web of Science ®Google Scholar
• LPF PTIN-H. A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837–842.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large b-cell lymphoma. N Engl J Med. 2018 Apr 12;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–1771.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014 Feb 20;123(8):1214–1217.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large b-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015 Sep 10;33(26):2848–2856.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood. 2013May16; 121(20)4021–4031. quiz 4250
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 Oct 1;30(28):3452–3459.
   PubMed Web of Science ®Google Scholar
• Bellas C, Garcia D, Vicente Y, et al. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS One. 2014;9(6):e98169.
   PubMed Web of Science ®Google Scholar
• Dodero A, Guidetti A, Marino F, et al. Dose-adjusted epoch and rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica. 2021. https://doi.org/10.3324/haematol.2021.278638.
   Google Scholar
• Horn H, Ziepert M, Wartenberg M, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29(7):1564–1570.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep. 2018 Apr 19;8(1):6267.
   PubMed Web of Science ®Google Scholar
• Petrella T, Copie-Bergman C, Brière J, et al. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol. 2017;28(5):1042–1049.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016 Nov;175(4):631–640.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009 Sep 10;114(11):2273–2279.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-Cell Lymphoma: a study by the Lunenburg Lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368.
   PubMed Web of Science ®Google Scholar
• Collinge BJ, Ben-Neriah S, Chong LC, et al. Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2020 137 2196–2208 .
   Web of Science ®Google Scholar
• Wang X, Huang Q High-Grade B-Cell Lymphoma Practical Lymph Node and Bone Marrow Pathology . . . 2020;157–174.
   Google Scholar
• Li J, Liu X, Yao Z, et al. High-grade B-Cell Lymphomas, not otherwise specified: a study of 41 cases. Cancer Manag Res. 2020;12:1903–1912.
   PubMed Web of Science ®Google Scholar
• Karunakaran P, Selvarajan G, Pk J, et al. High-Grade B-Cell Lymphoma,NOS: does prognosis end with the diagnosis? - a retrospective analysis. Blood. 2020;136(Supplement 1):28–29.
   Google Scholar
• Zayac A, Landsburg DJ, Hughes M, et al. High-grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): characteristics, treatment, and outcomes from 17 academic US centers. Blood. 2021;138(Supplement 1):455.
   Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398–1403.
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B Cell Lymphoma. Cell. 2017 Oct 5;171(2):481–494 e15.
   PubMed Web of Science ®Google Scholar
• Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020 May 14;135:1759–1771.
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B Cell Lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14.
   PubMed Web of Science ®Google Scholar
• Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2021 194 814–829 Aug 31.
   Google Scholar
• Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017–2022.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell Lymphoma. Clin Cancer Res. 2016 Aug 1;22(15):3801–3809.
   PubMed Web of Science ®Google Scholar
• Durani U, Ansell SM. CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk Lymphoma. 2021 Jul;21:1–9.
   Google Scholar
• Ma XB, Zhong YP, Zheng Y, et al. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med. 2018 Sep;7(9):4284–4295.
   PubMed Web of Science ®Google Scholar
• Tang H, Zhou H, Wei J, et al. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematology. 2019 Dec;24(1):446–454.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008 Aug;93(8):1195–1202.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Zhou S, et al. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol. 2019 Oct;37(4):360–367.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6:5615–5633.
   PubMedGoogle Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Aurer I, Dreyling M, Federico M, et al. Double hit lymphoma diagnosis and treatment in Europe—A cross-sectional survey of clinical practice by the EHA Lymphoma working party (EHA LyG). HemaSphere. 2020;4(6 e481).
   PubMed Web of Science ®Google Scholar
• Wilson WH, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May;97(5):758–765.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell Lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019 Jul 20;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• Dodero A, Guidetti A, Tucci A, et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019;33(4):1047–1051.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson cancer center clinical experience. Br J Haematol. 2014 Sep;166(6):891–901.
   PubMed Web of Science ®Google Scholar
• Ww CMJ, Cerdena S, Watkins M, et al. A multi-center analysis of the impact of dose level of R-EPOCH on outcomes of patients with double/triple-hit B-Cell Lymphoma. Blood. 2020;136:32–34.
   Google Scholar
• Laude MC, Lebras L, Sesques P, et al. First‐line treatment of double‐hit and triple‐hit lymphomas: survival and tolerance data from a retrospective multicenter French study. Am J Hematol. 2021;96(3):302–311.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617.
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Double-hit lymphoma: optimizing therapy. Hematology. 2021;2021(1):157–163.
   PubMedGoogle Scholar
• Gordon MJ, Westin JR. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? Leuk Lymphoma. 2021;1–11.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M, Reljic T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B‐cell lymphomas in first remission in the rituximab era: a systematic review and meta‐analysis. Cancer. 2019;125(24):4417–4425.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit Lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260–2267.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-Cell-like diffuse large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3538–3546.
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–1026.
   PubMed Web of Science ®Google Scholar
• Wilson W, Younes A, Staudt L, et al. Clinical impact of ibrutinib with R-CHOP in untreated non-GCB DLBCL co-expressing BCL2 and MYC genes in the phase 3 phoenix trial. Blood. 2019;134(Supplement_1):354.
   Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-Cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019 May 20;37(15):1285–1295.
   PubMed Web of Science ®Google Scholar
• Verner E, Johnston A, Pati N, et al. Efficacy of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed diffuse large B Cell Lymphoma: primary analysis of the Australasian leukaemia & Lymphoma group NHL29 study. Blood. 2021;138(Supplement 1):304.
   PubMedGoogle Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-Cell non-hodgkin Lymphoma. J Clin Oncol. 2015 Sep 1;33(25):2803–2811.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Trneny M, Davies A, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127–4137.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-Cell Lymphoma. J Clin Oncol. 2021 Apr 20;39(12):1317–1328.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of Lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-Cell Lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021 Apr 20;39(12):1329–1338.
   PubMed Web of Science ®Google Scholar
• Davies AJ. Precision medicine in DLBCL: are we there yet? J Clin Oncol. 2021 Apr 20;39(12):1314–1316.
   PubMed Web of Science ®Google Scholar
• Scheffold A, Jebaraj BMC, Stilgenbauer SV. Targeting BCL2 in hematological cancers. Recent Results Cancer Res. 2018;212:215–242.
   PubMedGoogle Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–609.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Ruppert AS, Giri S, et al. Randomized phase II/III Study of DA-EPOCH-R ± venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701. Blood. 2021;138(Supplement 1):523.
   Google Scholar
• Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721–2729.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20(7):998–1010.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. The POLARIX study: polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-Cell Lymphoma. Blood. 2021;138(Supplement 2):LBA-1-LBA-1.
   Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. polatuzumab vedotin in previously untreated diffuse large B-Cell Lymphoma. N Engl J Med. 2021;20(7):998–1010 .
   Google Scholar
• Roschewski M, Phelan JD, Pittaluga S, et al. Phase 2 study of acalabrutinib window prior to frontline therapy in untreated aggressive B-Cell Lymphoma: preliminary results and correlatives of response to acalabrutinib. Blood. 2021;138(Supplement 1):524.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Jaeger U, Bishop MR, Salles G, et al. Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed/refractory diffuse large B-Cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel in the juliet trial. Blood. 2020;136(Supplement 1):48–49.
   Google Scholar
• Chong EA, Chong ER, Landsburg DJ, et al. Anti-CD19 CAR-T for treatment of double expressor and double hit large B-Cell Lymphomas: a single institution real-world analysis. Blood. 2020;136(Supplement 1):19–20.
   Google Scholar
• Wei J, Mao Z, Wang N, et al. Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy. Clin Transl Med. 2020 Sep;10(5):e176.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Munoz J, et al. Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-Cell Lymphoma (LBCL). Blood. 2021;138(Supplement 1):739.
   PubMedGoogle Scholar
• Hill BT, Roth CJ, Kositsky R, et al. Impact of molecular features of diffuse large B-Cell Lymphoma on treatment outcomes with Anti-CD19 chimeric antigen receptor (CAR) t-cell therapy. Blood. 2021;138(Supplement 1):165.
   Google Scholar
• Shouval R, Alarcon Tomas A, Fein JA, et al. TP53 and CD19-directed chimeric antigen receptor t-cell (CAR-T) therapy in large B-Cell Lymphoma. Blood. 2021;138(Supplement 1):710.
   Google Scholar
• Jain MD, Ziccheddu B, Coughlin CA, et al. Genomic drivers of large B-Cell Lymphoma resistance to CD19 CAR-T therapy. Blood. 2021;138(Supplement 1):42.
   Google Scholar
• Ghosh N, Townsend W, Dickinson M, et al. Glofitamab plus R-CHOP Induces High Response Rates With Minimal Cytokine Release Syndrome (CRS) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin Lymphoma (NHL) and previously untreated (1l) diffuse large B-Cell Lymphoma (DLBCL): preliminary results from a dose-escalation and safety run-in phase ib study. Blood. 2021;138(Supplement 1):2479.
   Google Scholar
• Belada D, Christensen JH, Drott K, et al. Subcutaneous epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-Cell Lymphoma: preliminary results from a phase 1/2 Trial. Blood. 2021;138(Supplement 1):1413.
   Google Scholar